Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 7/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 4/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | CFD | P00746 | 3/20 | 0.37 |
| ▸ | F11 | P03951 | 3/20 | 0.37 |
| ▸ | TPSB2 | P20231 | 3/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4012487 | 1.00 | ADRB2 (0.45) | ADRB2ADRB3ELANEF2CFD | |
| SCHEMBL13589427 | 0.94 | ADRB2 (0.44) | ADRB2ADRB3ELANEF2CTSG | |
| SCHEMBL4256670 | 0.92 | ADRB2 (0.41) | ADRB2ADRB3ELANEF2CTSG | |
| SCHEMBL4256666 | 0.90 | ADRB3 (0.39) | ADRB2ADRB3ELANEF2CFD | |
| SCHEMBL5998831 | 0.90 | ADRB3 (0.39) | ADRB2ADRB3ELANEF2CFD | |
| SCHEMBL4255062 | 0.90 | ADRB3 (0.40) | ADRB2ADRB3ELANEF2CTSG | |
| SCHEMBL4260800 | 0.90 | ADRB3 (0.40) | ADRB2ADRB3ELANEF2CTSG | |
| SCHEMBL4256662 | 0.89 | ADRB2 (0.40) | ADRB2ADRB3ELANEF2CTSG | |
| SCHEMBL4386734 | 0.89 | MRGPRX4 (0.40) | ADRB2ADRB3ELANEF2CTSG | |
| SCHEMBL4386737 | 0.89 | MRGPRX4 (0.40) | ADRB2ADRB3ELANEF2CTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1624868-B9 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2009-08-12 | — | — | EP | disclosed |
| US-7482487-B2 | Phenylaminoethanol derivatives as β2 receptor agonists | PFIZER INC (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1624868-B1 | \"(2-HYDROXY-2-(4-HYDROXY-3-HYDOXYMETHYLPHENYL)-ETHYLAMINO)- PROPYL]PHENYL DERIVATIVES AS BETA2 AGONISTS | PFIZER LTD (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-20070264262-A1 | Phenylaminoethanol Derivates as Beta 2 Receptor Agonists | BROWN ALAN D | 2007-11-15 | — | — | US | disclosed |
| US-7268147-B2 | Compounds useful for the treatment of diseases | PFIZER INC (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1727789-A2 | PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS | Pfizer Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| WO-2006051373-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
| US-20060106107-A1 | L-tartrate salt of N-1-Adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl] phenyl}acetamide | JAMES KIM | 2006-05-18 | — | — | US | disclosed |
| WO-2005090287-A2 | PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| EP-1577291-A1 | Phenylethanolamine derivatives as beta-2 agonists | Pfizer Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577292-A1 | Phenylaminoethanol derivatives as beta2 receptor agonists | Pfizer Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
| US-20040229904-A1 | Compounds useful for the treatment of diseases | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-1477167-A1 | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists | Pfizer Limited (GB) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106107-A1 | L-tartrate salt of N-1-Adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl] phenyl}acetamide | ASPH, SLC6A12, AASDHPPT | ADRB2 498/4885ADRB3 694/4885ELANE 1201/4885 |
| US-20040229904-A1 | Compounds useful for the treatment of diseases | LTC4S, CYP11B1, CYP11B2 | ADRB2 901/4885ADRB3 802/4885ELANE 21/4885 |
| US-20070264262-A1 | Phenylaminoethanol Derivates as Beta 2 Receptor Agonists | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB3 5/4885ELANE 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.